Dual GIP and GLP-1 receptor agonist.
Acts on both GIP and GLP-1 pathways, producing greater glycemic and weight-loss effects than GLP-1-only agents.
Use
Weight management. Glycemic control. Metabolic syndrome.
Route
Subcutaneous injection, weekly.
Pairs with
Resistance training to preserve lean mass under deficit. Ipamorelin/CJC-1295 to support GH axis.
Status
FDA-approved (Mounjaro, Zepbound).